Search found 50 matches

by Ryan
Sat Nov 09, 2019 11:50 pm
Forum: ImetelChat
Topic: Dr. Uwe Platzbecker
Replies: 1
Views: 429

Dr. Uwe Platzbecker

In the ASH disclosures, I see that Dr P, who will be flying from Europe to be the presenter of the poster at ASH, is a Consultant for Novartis, a Consultant for Celgene, and a Consultant for Abbvie.

Rest assured these trials are in good hands and have the interest of large biopharmas.
by Ryan
Fri Nov 08, 2019 6:17 pm
Forum: ImetelChat
Topic: Ash posters
Replies: 9
Views: 1013

Re: Ash posters

In regards to the conference call, Dr. Rizo did most of the talking... She explained everything going on pretty succinctly imo, and the bit of color regarding sequential dosing was of interest. As she stressed, there is a lot of critical thinking to be done for these combos, completely new terrain a...
by Ryan
Thu Nov 07, 2019 6:56 pm
Forum: ImetelChat
Topic: Ash posters
Replies: 9
Views: 1013

Re: Ash posters

Patience is an easy concept but difficult in practice. These trials are supremely trying he patience of all (hand raise), but it doesn’t change that the scientific progress has been nothing short of spectacular. I’ll add the key executive hires in the past year into that adjective spectacular. Those...
by Ryan
Wed Nov 06, 2019 7:40 pm
Forum: ImetelChat
Topic: Ash posters
Replies: 9
Views: 1013

Re: Ash posters

What we found out this morning: - Combo trials are in play * Would love to see the AML combo re-emerge soon - MDS updated data is coming * Would love to see continued durability of Transfusion Independence. At what point is the TI 'tantamount to a cure'?;) - Pre-clinical research and investigation i...
by Ryan
Sun Oct 20, 2019 10:31 pm
Forum: ImetelChat
Topic: Dr. Rizo Abstracts
Replies: 1
Views: 695

Dr. Rizo Abstracts

As we know, Dr. Rizo has been a contributor on numerous abstracts during her distinguished career, and as has been documented here, her name has appeared on Imetelstat abstracts as part of the Janssen team. So I would not be surprised to see a new Imetelstat abstract released for ASH this year... ho...
by Ryan
Sun Oct 06, 2019 2:58 am
Forum: ImetelChat
Topic: New Corporate presentation
Replies: 4
Views: 1199

Re: New Corporate presentation

Fast Track was achieved much earlier in MDS Phase II because the goal of Transfusion Independence was achieved quickly for patients. Now the MDS indication is moving into late stage for patients with specific biomarkers, and again these TIs could come quickly. Within 6 months we could (*should) have...
by Ryan
Mon Sep 30, 2019 7:02 pm
Forum: ImetelChat
Topic: Full Separation from Janssen???
Replies: 2
Views: 766

Full Separation from Janssen???

The company has stated Q3 for full separation - and here we are, we hear nothing. Is this separation not a material event worthy of a PR? Or has it not happened? And while we’re at it, what is that very small 2nd Agreement all about, and why is it beneficial to Geron and owners? As you can see, more...
by Ryan
Sun Sep 29, 2019 2:02 am
Forum: ImetelChat
Topic: Novel Strategies for the Treatment of MF - Sept 2019
Replies: 1
Views: 551

Novel Strategies for the Treatment of MF - Sept 2019

Shout out to EarFool on Yahoo for posting this https://f1000research.com/articles/8-1662 Imetelstat is highlighted in the Novel Agents section. Man I could use a bone at next week’s conference - road weary - I suspect that the full freedom from Janssen will be announced at some point next week. That...
by Ryan
Sat Aug 10, 2019 9:28 pm
Forum: ImetelChat
Topic: P III
Replies: 5
Views: 2474

Re: P III

Finally is perhaps the understatement of the century Future is bright; success of Phase III MDS I peg above 95%. (Success of the MF FDA regulatory discussions, measured solely by accelerated approval, I’d put at around 45%) The past decade is full of successes for Imetelstat (and it’s team and colla...
by Ryan
Tue Aug 06, 2019 6:53 pm
Forum: ImetelChat
Topic: Imetelstat: The First Disease-Modifying Drug for Myelodysplastic Syndromes?
Replies: 4
Views: 1742

Imetelstat: The First Disease-Modifying Drug for Myelodysplastic Syndromes?

I don't think anyone has posted this fantastic overview from the conference / confirmation of the breakthrough data from Imetelstat presented. Imetelstat is the headline story of this conference review: https://www.emjreviews.com/hematology/congress-review/review-of-the-european-hematology-associati...
by Ryan
Mon Jul 29, 2019 8:11 pm
Forum: ImetelChat
Topic: Janssen Patent Application
Replies: 3
Views: 1826

Re: Janssen Patent Application

Hello J, Remember, Geron continues to have a, much smaller, deal with Janssen that continues to be in effect - it was a $5Million at signing, I believe the potential is $75 Million more plus single digits % royalties on any “product” revenues. This is a question that I am kicking myself for not aski...
by Ryan
Wed Jun 26, 2019 7:50 pm
Forum: ImetelChat
Topic: Tues conference
Replies: 5
Views: 2712

Re: Tues conference

Seems that every message board is filled with loathe from this meeting. If you look at the slides it tells a very different story. Change my handle from Ryan to Pollyanna I suppose :mrgreen: Even I tried to inject some magical happening that was going to happen, with thoughts of expanded cohorts for...
by Ryan
Tue Jun 25, 2019 12:54 am
Forum: ImetelChat
Topic: Tues conference
Replies: 5
Views: 2712

Re: Tues conference

Dr. Feneaux was quoted in OncLive article as saying a study in higher risk MDS patients was being planned. Do we hear something of either an academic institution stepping on to do a study or a corporate collaboration to include a high risk MDS cohort in the Phase III? That would be the only thing I ...
by Ryan
Sun Jun 16, 2019 8:55 pm
Forum: ImetelChat
Topic: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting
Replies: 3
Views: 2341

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

PS - 65% lower risk of death

Imetelstat is superior to Best Available Therapy for R/R patients in MF, that can be stated unequivocally.
by Ryan
Sun Jun 16, 2019 7:58 pm
Forum: ImetelChat
Topic: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting
Replies: 3
Views: 2341

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Thanks for posting. The statistical superiority of Imetelstat is not only clear but profound. We’re talking about over a year-and-a-half of continued life, that most key of KPI metrics. It’s not if but when Imetelstat is approved on this indication, and I suppose the when is early next year but even...
by Ryan
Wed Jun 12, 2019 7:15 pm
Forum: ImetelChat
Topic: Quotes from Shareholder meeting to focus on
Replies: 4
Views: 1534

Re: Quotes from Shareholder meeting to focus on

I’m really interested to get a follow-up on the “better looking data” this weekend. For MDS, improvement in TI durability would be great to see. For MF, it is intriguing that the Dr presenting is from the Moffitt Center, which is where the real world data comparator set was generated from... he trul...
by Ryan
Mon Jun 10, 2019 8:14 pm
Forum: ImetelChat
Topic: Quotes from Shareholder meeting to focus on
Replies: 4
Views: 1534

Re: Quotes from Shareholder meeting to focus on

Forgot to mention the intricacy of “So far, better looking data.” Considering that “So far” in this case means over a decade of preclinical and clinical successes, including near 100% CRs in ET and ‘tantamount to a cure’ in some MF cases according to the Mayo Clinic brochure, all built on a Nobel Pr...
by Ryan
Mon Jun 10, 2019 8:07 pm
Forum: ImetelChat
Topic: Quotes from Shareholder meeting to focus on
Replies: 4
Views: 1534

Quotes from Shareholder meeting to focus on

Here are the top quotes that I wrote down to focus on. What it does not include are Dr Rizo’s brilliant answers, which were too deeply reasoned and in-depth for me to jot down, frankly. Dr. Scarlett is certainly more ‘jottable’, and here are a couple of the doozies this past Thursday: “We have a Pha...
by Ryan
Sun Jun 09, 2019 9:44 pm
Forum: ImetelChat
Topic: The 2019 Annual Shareholders Meeting: My thoughts.
Replies: 13
Views: 3154

Re: The 2019 Annual Shareholders Meeting: My thoughts.

Great updates. There really is nothing to add but, let's wait it out. I think with so many bumps in the road, as detailed by Biopearl, it's incredibly difficult to not be jaded, however cleaning the slate on history it becomes clear that Imetelstat is indeed a "soon-to-be" first-in-class drug with a...